If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"","arm_groups":[{"arm_group_label":"Fosamprenavir treatment group","arm_group_description":"Fosamprenavir is a drug used for the treatment of HIV infections. It is used in a small number of cases often in addition with the large number of drugs.","arm_type":""}],"assignment":"","brief_summary":"Fosamprenavir is an orphan drug used in an extremely small number of cases, often concomitantly with a large number of drugs for the treatment of Human Immunodeficiency Virus (HIV) infection. The study describes a HIV-related drug (HRD) joint use-results survey which will be conducted in Japan as there is no clinical study data from Japanese subjects with HIV infection. The survey will be conducted at institutions that have HIV infection specialists and treat many subjects with HIV infection. Approximately 40 subjects per investigator will be enrolled. A drug use-results survey of Fosamprenavir will be also performed as a HRD joint use-results survey. The objective of the study is to collect the safety.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Drug Use Investigation for Lexiva tablet (HRD Cooperative Investigation)","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 19:34:50","criteria":"Inclusion Criteria: - Subjects treated with Fosamprenavir.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 2","display_phase_internal":"PHASE_2","display_status":"Finalized","display_status_internal":"RECSTATUS_O_COMPLETED","endpoint":"","enrollment":"1","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"none","id":"75f65fc5-9720-510b-a577-404cb0e3f83d","internal":{"content":null,"contentDigest":"4562097c2ae42de525e6100d899ebe36","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Subjects treated with Fosamprenavir.","interventions":[{"arm_group_label":"Fosamprenavir treatment group","intervention_description":"The HRD joint survey will be conducted using a common case report form (CRF). In the HRD joint survey, subject enrollment, data entry in the CRFs, reinvestigations and other relevant matters will be carried out using an electronic data capture (EDC) system.","intervention_name":"HRD joint survey","intervention_type":"other"}],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":["Fosamprenavir","HIV","Infection","Lexiva tablet","HRD survey"],"last_follow_up_date":"12/01/2014 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"","maximum_age":null,"minimum_age":null,"minimum_age_raw":"","modified_date":"10/01/2018 22:21:38","number_of_arms":"","observational_design":{"biospecimen_description":"NA","biospecimen_retention":"None retained","number_of_groups":"","observational_study_design":"Cohort","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":"Cross-sectional"},"official_title":"Drug Use Investigation for Lexiva tablet (HRD Cooperative Investigation)","org_study_id":"112334","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":["Japan: Pharmaceutical and Medical Device Agency"]},"phase":"Phase 2","primary_compl_date":"12/01/2014 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Number of subjects with adverse drug reactions (ADRs)","outcome_time_frame":"Up to 10 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with abnormal blood biochemistry parameters","outcome_time_frame":"Up to 10 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Evaluation of Center for Disease Control and Prevention (CDC) classification","outcome_time_frame":"Up to 10 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with serious and unknown ADRs","outcome_time_frame":"Up to 10 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of occurrences of characteristic adverse reactions in subjects with hemophilia","outcome_time_frame":"Up to 10 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of occurrences of AEs","outcome_time_frame":"Up to 10 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of occurrences of ADRs","outcome_time_frame":"Up to 10 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Evaluation of interactions with concomitant medications","outcome_time_frame":"Up to 10 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of HIV- Ribonucleic acid (RNA) copies","outcome_time_frame":"Up to 10 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with abnormal urinalysis parameters","outcome_time_frame":"Up to 10 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with Adverse Reactions (AEs)","outcome_time_frame":"Up to 10 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Evaluation of Cluster of Differentiation (CD4) lymphocyte count","outcome_time_frame":"Up to 10 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with abnormal hematology parameters","outcome_time_frame":"Up to 10 years","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["N/A"]},"start_date":"08/01/2005 00:00:00","study_type":"Observational","therapeutic_area":"","citations":[],"is_section_801":null}},"pageContext":{"studyId":"112334"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}